Incyte (INCY) Financial Analysis & Valuation | Quarter Chart
Incyte (INCY)
INCYPrice: $114.66
Fair Value: 🔒
🔒score
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growt... more
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commerci... more
Description
Shares
| Market Cap | $22.91B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William J. Meury |
| IPO Date | 1993-11-04 | CAGR | 0.36% |
| Employees | 2,617 | Website | www.incyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.09% | Total Yield | 0.09% |
INCY chart loading...
Fundamentals
Technicals
| Enterprise Value | $18.83B | P/E Ratio | 15.41 |
| Forward P/E | 12.47 | PEG Ratio | 0.19 |
| P/S Ratio | 5.05 | P/B Ratio | 4.87 |
| P/CF Ratio | 17.8 | P/FCF Ratio | 18.65 |
| EPS | $7.44 | EPS Growth 1Y | 2112.5% |
| EPS Growth 3Y | 389.56% | EPS Growth 5Y | 226.19% |
| Revenue Growth 1Y | 21.48% | Gross Margin | 0.92% |
| Operating Margin | 0.27% | Profit Margin | 0.27% |
| ROE | 0.29% | ROA | 0.2% |
| ROCE | 0.25% | Current Ratio | 3.68 |
| Quick Ratio | 3.6 | Cash Ratio | 2.32 |
| Debt/Equity | 0.01 | Interest Coverage | 620.56 |
| Altman Z Score | 9.97 | Piotroski Score | 5 |